



**MINISTRY OF HEALTH**  
**PHARMACY AND POISONS BOARD**

**RAPID ALERT NOTIFICATION OF A FALSIFIED AUGMENTIN 625MG  
AND 875MG/125MG**

		Reference Number : <b>2025/004</b>
1. To: <b>World Health Organization, Market Authorization Holders, Distributors, Retailers and Consumers</b>		
2. Product Class of Defect: <b>Class 1</b>		3. <b>Falsified</b>
4. Product : <b>Augmentin 625mg and Augmentin 875mg/125mg (1g)</b>	5. Marketing Authorization Number : <b>N/A</b>  <i>For use in humans</i>	
6. Brand/Trade Name : <b>Augmentin 625mg and 875mg/125mg (1g)</b>	7. INN or Generic Name : <b>Amoxicillin + Clavulanic acid</b>	
8. Dosage Form : <b>Oral</b>	9. Strength: <b>625mg and 875mg/125mg (1g)</b>	
10. Batch Numbers: <b>SG2S, 8X3K and EU7C</b>	11. Expiry Date : <b>24-07-2026: (BN.8X3K) 625mg</b>  <b>18-01-2026: (SG2S) 875mg/125mg (1g)</b> <b>30-11-2026 : (EU7C) 875mg/125mg (1g)</b>	
12. Pack size and Presentation: <b>14 blister packed tablets in a box</b>	13. Date of Manufacture: <b>24-07-2023 : (8X3K) 625mg</b>  <b>18-01-2023 : (SG2S) 875mg/125mg (1g)</b> <b>01-11-2023 : (EU7C) 875mg/125mg (1g)</b>	
14. Marketing Authorization Holder : <b>GlaxoSmithKline Trading Services , Dublin , Ireland</b>		
15. Manufacturer: <b>Stated as SmithKline Beecham, Worthing Limited, United Kingdom</b>	16. Recalling Firm (if different): <b>N/A</b>	
15.1 Where the defect is attributed to a manufacturing site, site where defect occurred: <b>N/A</b>		
17. Recall Number Assigned (if available): <b>N/A</b>		

18. Details of Falsification : <ul style="list-style-type: none"> <li>• <b>The print on the blister strip lidding foil is a darker purple and has a thicker font size than the authentic product.</b></li> <li>• <b>The embossing on the printed side seems slightly deeper than on a genuine tablet.</b></li> <li>• <b>The patient information leaflet included with the suspected counterfeit sample has several formatting errors and incorrect spacing between words.</b></li> </ul>	
19. Information on distribution including exports (type of customer, e.g. hospitals): <b>consumer/patients.</b>	
20. Action taken by Issuing Authority: <b>Rapid Alert</b>	
21. Proposed Action: <b>Pharmaceutical outlets, healthcare facilities, healthcare professionals and members of the public to IMMEDIATELY CEASE further distribution, sale, issuing, or use of the outlined batches immediately.</b>	
22. From (Issuing Authority): <b>Kenya Pharmacy and Poisons Board</b>	23. For <b>Feedback</b>  Contact:  <a href="mailto:pms@ppb.go.ke">pms@ppb.go.ke</a>  Telephone:  <b>0795743049</b>
24. Date: <b>24<sup>th</sup> April 2025</b>	